- Expecting to create synergy effect between SK chemicals’ marketing capability
and Bayer’s excellent products
- Expecting excellent marketing capability and experience in regard with
circulatory medicines such as Ginexin and Cosca
SK chemicals (CEO Park Man-Hoon) and Byer Korea will sell Aspirin Protect an Adalat Oros together.
SK chemicals announced that the company and Bayer signed an agreement for joint sales of cardiovascular disorder medicine Aspirin Protect (active ingredient: Aspirin) and high blood pressure medicine Adalat Oros (active ingredient: Nifedipine).
Through this agreement, SK chemicals will take charge of sales and marketing of these two medicines in hospitals with less than 100 sickbeds starting September 2016.
Aspirin Protect, a low dose aspirin (acetyl salicylic acid 100mg), is one of representative drugs of Bayer Korea that prevents the thrombus formation, thus reduces the risk of cardiovascular diseases such as stroke and myocardial infarction.
According to the announcement of WHO in 2014, taking aspirins to manage acute myocardial infarction is one of chronic disease management methods against the cost.
In addition, US Preventive Services Task Forces (USPSTF) is recommending the use of low dose aspirin for the age group of 50 -69 with high risk cardio-cerebrovascular disease in order to prevent the disease.
Adalat Oros is a Calcium Channel Blocker (CCB) hypertension drug that delivers Nifedipine with constant speed for 24 hours by applying Osmotic Controlled-release Oral Delivery (OROS) technology.
As it shows great effectiveness in dropping blood pressure at the early stage, Adalat Oros is one of representative CCB drugs that is being prescribed for long-term use.
Meanwhile, Ingrid Drexel, President of Bayer Korea, said, “It is a great pleasure to sign a joint sales agreement with SK chemicals, which is possessing an excellent marketing capability. We are expecting to make a contribution to improvement of the quality of patient’s life, let alone enhancing market position by combining capabilities of the two companies.”
Park Man-Hoon, CEO of SK chemicals, said, “We are accumulating marketing capabilities in regard with circular system medicines such as circulation improvement agent Ginexin and hypertension drug Cosca. We will focus on expanding market share of Aspirin Protect and Adalat Oros.”